Latest Conference Articles

January 20th 2023, 8:42pm

Gastrointestinal Cancers Symposium (ASCO GI)

In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.

January 20th 2023, 6:05pm

Gastrointestinal Cancers Symposium (ASCO GI)

Second-line lenvatinib may produce a survival benefit in patients with advanced hepatocellular carcinoma who have progressed on immunotherapy.

January 20th 2023, 1:41am

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.

January 20th 2023, 1:38am

Gastrointestinal Cancers Symposium (ASCO GI)

Frontline zolbetuximab plus mFOLFOX6 significantly improved progression-free and overall survival vs placebo/mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial.

January 20th 2023, 1:20am

Gastrointestinal Cancers Symposium (ASCO GI)

Nivolumab in combination with chemotherapy or ipilimumab maintained a clinically meaningful overall survival benefit vs chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

January 20th 2023, 12:54am

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of nivolumab (Opdivo) and chemotherapy continued to provide a clinically meaningful long-term survival benefit and deeper responses than chemotherapy alone in previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, according to 3-year follow-up data from the phase 3 CheckMate-649 trial.

January 19th 2023, 11:29pm

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr virus–negative gastric or gastroesophageal junction adenocarcinoma.

January 19th 2023, 9:28pm

Gastrointestinal Cancers Symposium (ASCO GI)

Clinicopathological features of HER2-low advanced gastric cancer were distinct and distinguishable from those of HER2-positive or -negative disease, according to retrospective findings from a single-institution study that were presented at the 2022 Gastrointestinal Cancers Symposium.

January 8th 2023, 11:00am

Neoadjuvant treatment with SHR-1701 with or without chemotherapy followed by surgery or radiotherapy induced responses in more than half of patients with stage III unresectable non–small cell lung cancer and increased resectability in those assigned to definitive surgery.

December 16th 2022, 1:07am

ASH Annual Meeting and Exposition

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

December 15th 2022, 4:49pm

ASH Annual Meeting and Exposition

Tisagenlecleucel elicited durable efficacy and a favorable long-term safety profile in the real-world setting of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

December 14th 2022, 4:09pm

ASH Annual Meeting and Exposition

Olutasidenib monotherapy induced high complete response rates with a manageable toxicity profile in patients with relapsed/refractory acute myeloid leukemia harboring IDH1 mutations.

December 14th 2022, 3:54pm

ASH Annual Meeting and Exposition

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

December 13th 2022, 10:35pm

ASH Annual Meeting and Exposition

BGB-11417, when given alone or in combination with zanubrutinib, elicited encouraging responses and minimal residual disease negativity rates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to preliminary data from a phase 1 trial.

December 13th 2022, 9:34pm

ASH Annual Meeting and Exposition

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

December 13th 2022, 8:52pm

ASH Annual Meeting and Exposition

Consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation improved progression-free survival vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.

December 13th 2022, 8:47pm

ASH Annual Meeting and Exposition

Among patients with newly diagnosed high-risk multiple myeloma, treatment with BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100%, with all treated patients evaluable for minimal residual disease showing minimal residual disease negativity to 12 months.

December 13th 2022, 8:04pm

ASH Annual Meeting and Exposition

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

December 13th 2022, 6:40pm

ASH Annual Meeting and Exposition

Administration of cyclophosphamide, tacrolimus, and mycophenolate mofetil improved 1-year GVHD relapse-free survival compared with tacrolimus plus methotrexate in patients with hematologic malignancies undergoing reduced intensity conditioning allogeneic hematopoietic cell transplantation.

December 13th 2022, 6:20pm

ASH Annual Meeting and Exposition

The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.